title: Secondary Ph+ acute lymphoblastic leukemia after temozolomide.
authors.forename: Serena
authors.initials: S
authors.lastname: De Vita
authors.forename: Silvia
authors.initials: S
authors.lastname: De Matteis
authors.forename: Luca
authors.initials: L
authors.lastname: Laurenti
authors.forename: Patrizia
authors.initials: P
authors.lastname: Chiusolo
authors.forename: Giovanni
authors.initials: G
authors.lastname: Reddiconto
authors.forename: Alessia
authors.initials: A
authors.lastname: Fiorini
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Leone
authors.forename: Simona
authors.initials: S
authors.lastname: Sica
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001549:Benzamides; D016543:Central Nervous System Neoplasms / Q000188:drug therapy*; D003606:Dacarbazine / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000139:chemically induced*; D008297:Male; D010879:Piperazines / Q000008:administration & dosage; D011743:Pyrimidines / Q000008:administration & dosage; D000077204:Temozolomide
chemical_list: D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D003606:Dacarbazine; D000068877:Imatinib Mesylate; D000077204:Temozolomide